Aegerion Pharmaceuticals, Inc. (AEGR) Posts Q2 adj.-Loss of 6c/Share

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) reported Q2 EPS of ($0.06), $0.35 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $36 million versus the consensus estimate of $35.4 million.

For earnings history and earnings-related data on Aegerion Pharmaceuticals, Inc. (AEGR) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• SuperCom (SPCB) Tops Q3 EPS by 43c
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation